Bladder Cancer Canada and its Medical Advisory Board have been advised by Merck Canada that they will be experiencing limited supply of Bacillus Calmette-Guerin (BCG) in the coming months.
Merck has established an allocation plan effective immediately and will keep information updated at https://www.drugshortagescanada.ca/drug/4066
Merck expects to fulfill between 75% and 100% of the normal demand during this time. Allocation based on historical customer orders has been implemented to ensure the available quantity is efficiently provided to patients. The anticipated end date is October 2019.
Below is an approach for consideration by physicians who treat bladder cancer to address the shortage of BCG should limited supply be realized.
Download the document here: Approach to Address BCG Shortage (Nov 2018)
The Medical Advisory Board of Bladder Cancer Canada and the CUA Guidelines Committee have reviewed and support these suggestions.
Bladder Cancer Canada will continue to update you as we receive more information.